86 related articles for article (PubMed ID: 1924788)
1. Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon.
Brown JJ; Duncan JR; Heiken JP; Balfe DM; Corr AP; Mirowitz SA; Eilenberg SS; Lee JK
Radiology; 1991 Nov; 181(2):455-60. PubMed ID: 1924788
[TBL] [Abstract][Full Text] [Related]
2. Intraluminal contrast enhancement and MR visualization of the bowel wall: efficacy of PFOB.
Rubin DL; Muller HH; Nino-Murcia M; Sidhu M; Christy V; Young SW
J Magn Reson Imaging; 1991; 1(3):371-80. PubMed ID: 1802151
[TBL] [Abstract][Full Text] [Related]
3. Perflubron as an oral contrast agent for MR imaging: results of a phase III clinical trial.
Mattrey RF; Trambert MA; Brown JJ; Young SW; Bruneton JN; Wesbey GE; Balsara ZN
Radiology; 1994 Jun; 191(3):841-8. PubMed ID: 8184076
[TBL] [Abstract][Full Text] [Related]
4. Reducing metallic artifacts in postoperative spinal imaging: usefulness of IDEAL contrast-enhanced T1- and T2-weighted MR imaging--phantom and clinical studies.
Cha JG; Jin W; Lee MH; Kim DH; Park JS; Shin WH; Yi BH
Radiology; 2011 Jun; 259(3):885-93. PubMed ID: 21386053
[TBL] [Abstract][Full Text] [Related]
5. I.v. glucagon use in pediatric MR enterography: effect on image quality, length of examination, and patient tolerance.
Dillman JR; Smith EA; Khalatbari S; Strouse PJ
AJR Am J Roentgenol; 2013 Jul; 201(1):185-9. PubMed ID: 23789674
[TBL] [Abstract][Full Text] [Related]
6. Perfluoroctylbromide: a liver/spleen-specific and tumor-imaging ultrasound contrast material.
Mattrey RF; Scheible FW; Gosink BB; Leopold GR; Long DM; Higgins CB
Radiology; 1982 Dec; 145(3):759-62. PubMed ID: 7146409
[TBL] [Abstract][Full Text] [Related]
7. MR imaging of Crohn disease: use of perflubron as a gastrointestinal contrast agent.
Anderson CM; Brown JJ; Balfe DM; Heiken JP; Borrello JA; Clouse RE; Pilgram TK
J Magn Reson Imaging; 1994; 4(3):491-6. PubMed ID: 8061454
[TBL] [Abstract][Full Text] [Related]
8. Perfluorochemicals as gastrointestinal contrast agents for MR imaging: preliminary studies in rats and humans.
Mattrey RF; Hajek PC; Gylys-Morin VM; Baker LL; Martin J; Long DC; Long DM
AJR Am J Roentgenol; 1987 Jun; 148(6):1259-63. PubMed ID: 3495156
[TBL] [Abstract][Full Text] [Related]
9. Gadopentetate dimeglumine as a bowel contrast agent: safety and efficacy.
Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Langer M; Claussen C; Felix R
Radiology; 1991 Feb; 178(2):503-8. PubMed ID: 1987615
[TBL] [Abstract][Full Text] [Related]
10. Positive bowel contrast agent for MR imaging of the abdomen: phase II and III clinical trials.
Patten RM; Lo SK; Phillips JJ; Bowman SC; Glazer GM; Wall SD; Bova JG; Harris RD; Wheat RL; Johnson CD
Radiology; 1993 Oct; 189(1):277-83. PubMed ID: 8372205
[TBL] [Abstract][Full Text] [Related]
11. MR enteroclysis using iron oxide particles (ferristene) as an endoluminal contrast agent: an open phase III trial.
Boraschi P; Braccini G; Gigoni R; Cartei F; Perri G
Magn Reson Imaging; 2004 Oct; 22(8):1085-95. PubMed ID: 15527995
[TBL] [Abstract][Full Text] [Related]
12. The value of hyoscine butylbromide in pelvic MRI.
Johnson W; Taylor MB; Carrington BM; Bonington SC; Swindell R
Clin Radiol; 2007 Nov; 62(11):1087-93. PubMed ID: 17920868
[TBL] [Abstract][Full Text] [Related]
13. The value of barium as a gastrointestinal contrast agent in MR imaging: a comparison study in normal volunteers.
Ros PR; Steinman RM; Torres GM; Burton SS; Panaccione JL; Rappaport DC; McGorray SP
AJR Am J Roentgenol; 1991 Oct; 157(4):761-7. PubMed ID: 1892032
[TBL] [Abstract][Full Text] [Related]
14. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors.
Kubota T; Yamada K; Kizu O; Hirota T; Ito H; Ishihara K; Nishimura T
J Magn Reson Imaging; 2005 Jun; 21(6):694-700. PubMed ID: 15906343
[TBL] [Abstract][Full Text] [Related]
15. MR imaging evaluation of the activity of Crohn's disease.
Koh DM; Miao Y; Chinn RJ; Amin Z; Zeegen R; Westaby D; Healy JC
AJR Am J Roentgenol; 2001 Dec; 177(6):1325-32. PubMed ID: 11717076
[TBL] [Abstract][Full Text] [Related]
16. T2-weighted MR imaging in the assessment of cirrhotic liver.
Hussain HK; Syed I; Nghiem HV; Johnson TD; Carlos RC; Weadock WJ; Francis IR
Radiology; 2004 Mar; 230(3):637-44. PubMed ID: 14739306
[TBL] [Abstract][Full Text] [Related]
17. MR imaging of peritoneal disease: comparison of contrast-enhanced fast multiplanar spoiled gradient-recalled and spin-echo imaging.
Low RN; Sigeti JS
AJR Am J Roentgenol; 1994 Nov; 163(5):1131-40. PubMed ID: 7976889
[TBL] [Abstract][Full Text] [Related]
18. Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging.
Kvistad KA; Rydland J; Vainio J; Smethurst HB; Lundgren S; Fjøsne HE; Haraldseth O
Radiology; 2000 Aug; 216(2):545-53. PubMed ID: 10924584
[TBL] [Abstract][Full Text] [Related]
19. [Optimization of dosage and exam technique in the use of oral contrast media in magnetic resonance].
Broglia L; Tortora A; Maccioni F; Arpesani R; Marcelli G; Ascarelli A; Rossi P
Radiol Med; 1999 May; 97(5):365-70. PubMed ID: 10432968
[TBL] [Abstract][Full Text] [Related]
20. Squamous cell carcinoma of the oral cavity: MR findings and value of T1-versus T2-weighted fast spin-echo images.
Yasumoto M; Shibuya H; Takeda M; Korenaga T
AJR Am J Roentgenol; 1995 Apr; 164(4):981-7. PubMed ID: 7726062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
